Palmitelaidic Acid (9-trans-Hexadecenoic acid)
(Synonyms: 软脂酸; 9-trans-Hexadecenoic acid; trans-Palmitoleic acid) 目录号 : GC33765
A dietary fatty acid
Cas No.:10030-73-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Mice: Male C57BL/6J wild type and PPARα-KO mice are fed a high-fat diet or a standard diet for 12 weeks. In the last two weeks, the HF-fed mice are treated daily with oleic acid (300 mg/kg of body weight) or palmitoleic acid (00 mg/kg of body weight) by oral gavage. After 12 weeks, the mice are fasted for 6 h, injected with insulin or PBS vehicle. Blood and liver samples are collected and stored for the further analysis of RNA and protein expression[2]. |
References: [1]. Frigolet ME, et al. The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease. | |
Palmitelaidic acid is a trans isomer of palmitoleic acid and dietary fatty acid that has been found in dairy fat products and various partially hydrogenated oils.1,2 It decreases nitric oxide (NO) production and levels of soluble E-selectin in isolated human aortic endothelial cells (HAECs) when used at a concentration of 20 ?M.1 Palmitelaidic acid (49 ?M) inhibits Sendai virus-induced hemolysis of isolated human erythrocytes.3 Increased serum levels of palmitelaidic acid are associated with higher levels of LDL, but lower levels of triglycerides, fasting insulin, blood pressure, and incidence of diabetes.2
1.Livingstone, K.M., Givens, D.I., Jackson, K.G., et al.Comparative effect of dairy fatty acids on cell adhesion molecules, nitric oxide and relative gene expression in healthy and diabetic human aortic endothelial cellsAtherosclerosis234(1)65-72(2014) 2.Mozaffarian, D., de Oliveira Otto, M.C., Lemaitre, R.N., et al.trans-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: The multi-ethnic study of atherosclerosis (MESA)Am. J. Clin. Nutr.97(4)854-861(2013) 3.MacDonald, R.C., Ore, V.D., and MacDonald, R.I.Inhibition of sendai virus-induced hemolysis by long chain fatty acidsVirology134(1)103-117(1984)
| Cas No. | 10030-73-6 | SDF | |
| 别名 | 软脂酸; 9-trans-Hexadecenoic acid; trans-Palmitoleic acid | ||
| Canonical SMILES | CCCCCC/C=C/CCCCCCCC(O)=O | ||
| 分子式 | C16H30O2 | 分子量 | 254.41 |
| 溶解度 | Ethanol : 100 mg/mL (393.07 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9307 mL | 19.6533 mL | 39.3066 mL |
| 5 mM | 0.7861 mL | 3.9307 mL | 7.8613 mL |
| 10 mM | 0.3931 mL | 1.9653 mL | 3.9307 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。